그람 양성 감염증 시장 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the gram-positive bacterial infections market size is expected to grow from USD 15.78 billion in 2025 to USD 16.70 billion in 2026 and is forecast to reach USD 22.20 billion by 2031 at 5.86% CAGR over 2026-2031.

This report is Segmented by Product Category (Therapeutics, Diagnostics, and More), Pathogen (Staphylococcus Aureus, and More), Disease Indication (Pneumonia, Sepsis/BSI, SSTI, Pharyngitis, and More), End User (Hospitals, Reference Laboratories, and More), and Geography (North America, South America, Europe, and More). Market Forecasts are Provided in Terms of Value (USD).

Global Gram-positive Bacterial Infections Market Trends and Insights

Rising Prevalence of Gram-Positive Infections

In 2024, invasive S. aureus bloodstream infections reached 37.9 per 100,000 population in EU/EEA countries, ranking second only to E. coli bacteremia. The backlog of surgeries during the pandemic has led to an increase in prosthetic joint implantations, raising the risk of late-onset staphylococcal infections over the lifespan of these devices. Between 2020 and 2024, the incidence of invasive S. pneumoniae disease doubled as respiratory pathogens began circulating more widely. Clostridioides difficile remains the leading cause of healthcare-associated diarrhea, resulting in 223,900 hospitalizations and 12,800 deaths annually in the U.S. Additionally, recurrence rates after vancomycin therapy remain as high as 30%.

Increasing Number of Drug Approvals & Late-Stage Pipelines

The 2025 antibacterial pipeline includes 90 clinical-stage assets, with half targeting gram-positive organisms. Tostatoxumab, a human monoclonal antibody, successfully completed Phase 3 trials for severe S. aureus pneumonia, demonstrating significant benefits for elderly patients and prompting a confirmatory study focused on this demographic. The anti-biofilm antibody TRL1068 showed promising results in Phase 1 trials for prosthetic joint infections, achieving synovial penetration and bacterial load reduction, thereby validating non-traditional treatment approaches.

Escalating Antibiotic Resistance Among Gram-Positive Pathogens

Linezolid resistance now appears in multiple regions via 23S rRNA mutation and cfr gene uptake, curbing therapy length and success. Cambodia's surveillance logged 12.5% extensively drug-resistant Neisseria gonorrhoeae isolates in 2023, underscoring how resistance traits spread quickly even in lower-use settings. Global antibiotic consumption climbed 16.3% between 2016 and 2023, with forecasts of 52.3% growth by 2030 if unchecked, accelerating selection pressure. These patterns threaten current pipelines and require simultaneous investment in prevention, diagnostics, and novel mechanisms.

Other drivers and restraints analyzed in the detailed report include:

1. Growing Healthcare Spending in Emerging Economies
2. Adoption Of Rapid Molecular Diagnostics Enabling Targeted Therapy
3. Patent Expiries Driving Generic Erosion

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Diagnostics represented the smaller revenue base in 2025, yet they are set to post a 6.79% CAGR through 2031, the swiftest growth among product categories. Stewardship mandates that favor same-day organism detection reinforce hospital demand for multiplex PCR panels and rapid phenotypic systems. Glycopeptides retained an 18% slice of therapeutic revenue, but margin pressure is accelerating as clinical guidance adopts shorter, higher-dose courses requiring therapeutic drug monitoring.

Rapid testing also underpins greater use of oral step-down regimens, boosting oxazolidinone demand. Hospitals gain workflow efficiencies when multiplex systems reduce ancillary culture labor, while payers view faster de-escalation as a lever to trim length of stay. These operational savings are beginning to offset the higher upfront cost of molecular tests, further widening the diagnostics adoption curve and enlarging the gram-positive bacterial infections market.

Staphylococcus aureus infections, including methicillin-resistant strains, delivered 28.5% of 2025 pathogen revenue, reflecting their central role in surgical site and indwelling device infection. Despite a 20.4% decline in MRSA bloodstream incidence across the EU, hospital networks still reserve anti-MRSA cephalosporins and lipoglycopeptides for high-risk cohorts.

Clostridioides difficile is projected to grow at 6.96% CAGR to 2031, the fastest pathogen trajectory, fueled by agents such as CRS3123 and ibezapolstat that spare gut microbiota and sharply cut recurrence. Regulatory agencies are signaling acceptance of composite endpoints that emphasize sustained cure, a development likely to accelerate approval timelines and solidify commercial uptake once Phase 3 data read out.

Geography Analysis

North America delivered 41.25% of 2025 revenue, anchored by 6,200 U.S. hospital laboratories and sustained capital budgets for rapid molecular systems. Urban facilities favor platforms such as Accelerate Pheno and BioFire FilmArray; however, rural centers still rely on manual culture workflows that can exceed 96 hours before result release, leaving opportunity for low-footprint direct-from-blood solutions. Federal stewardship targets now link reimbursement bonuses to timely de-escalation metrics, further entrenching rapid diagnostics.

Europe recorded a 20.4% decline in MRSA bloodstream incidence from 2019 to 2024, yet eight countries documented vancomycin-resistant Enterococcus faecium prevalence above 50%. Germany's 2025 technology assessment endorsed reimbursement for systems that trim AST turnaround by at least 12 hours. QuickMIC validation met this threshold, prompting procurement consortia to negotiate volume-linked contracts. With combined penicillin and macrolide resistance in S. pneumoniae at 11.1%, guideline panels now recommend empiric regimens containing either higher-dose beta-lactams or fluoroquinolones in community-acquired pneumonia.

Asia-Pacific is poised for an 8.25% CAGR through 2031, the highest regional pace. China's 8.2% annual healthcare spending expansion between 2020 and 2025 has lifted procurement budgets for automated blood culture and MALDI-TOF identification. India's Ayushman Bharat scale-up enables district hospitals to transition from syndromic management to culture-based therapy. Harmonization with EUCAST breakpoints across China, India, and Brazil tightens susceptibility interpretation for glycopeptides and oxazolidinones, reducing treatment failure masquerading as susceptibility. South America contributes 6% of global 2025 revenue; Brazil's breakpoint adoption is already steering hospitals toward reserve agents for refractory VRE and MRSA infections.

1. Abbott Laboratories
2. AstraZeneca
3. Basilea Pharmaceutica Ltd.
4. Becton Dickinson & Co.
5. bioMerieux
6. Cepheid (Danaher)
7. Cumberland Pharmaceuticals
8. Dr Reddy's Laboratories Ltd.
9. GlaxoSmithKline
10. Hikma Pharmaceuticals
11. Johnson & Johnson
12. Lupin
13. Melinta Therapeutics
14. Merck
15. Novartis
16. Paratek Pharmaceuticals
17. Pfizer
18. Roche
19. Sanofi
20. Shionogi & Co., Ltd.
21. Sun Pharma Industries Ltd.
22. Thermo Fisher Scientific

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Prevalence of Gram-Positive Infections
  • 4.2.2 Increasing Number of Drug Approvals & Late-Stage Pipelines
  • 4.2.3 Growing Healthcare Spending in Emerging Economies
  • 4.2.4 Adoption of Rapid Molecular Diagnostics Enabling Targeted Therapy
  • 4.2.5 Bundled-Payment Rules Boosting Prophylactic Narrow-Spectrum Use
  • 4.2.6 Climate-Driven Geographic Expansion of Gram-Positive Pathogens
• 4.3 Market Restraints
  • 4.3.1 Escalating Antimicrobial Resistance Among Gram-Positive Bacteria
  • 4.3.2 Patent Expiries Driving Generic Erosion
  • 4.3.3 Diagnostic Stewardship Curbing Unnecessary Test Ordering
  • 4.3.4 VC Pullback for Narrow-Spectrum Antibiotic Start-Ups
• 4.4 Value / Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Buyers
  • 4.7.3 Bargaining Power of Suppliers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Intensity of Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Product Category
  • 5.1.1 Therapeutics
    • 5.1.1.1 ?-lactam antibiotics
    • 5.1.1.2 Cephalosporins
    • 5.1.1.3 Penicillins
    • 5.1.1.4 Fluoroquinolones
    • 5.1.1.5 Lipopeptides
    • 5.1.1.6 Oxazolidinones
    • 5.1.1.7 Glycopeptides
    • 5.1.1.8 Vaccines & mAbs
  • 5.1.2 Diagnostics
    • 5.1.2.1 Culture & susceptibility testing
    • 5.1.2.2 Rapid molecular (PCR, isothermal)
    • 5.1.2.3 Immunoassays
    • 5.1.2.4 Point-of-care lateral-flow
  • 5.1.3 Adjunctive Prevention Products
• 5.2 By Pathogen
  • 5.2.1 Staphylococcus aureus (incl. MRSA)
  • 5.2.2 Streptococcus pneumoniae
  • 5.2.3 Enterococcus faecalis/faecium (incl. VRE)
  • 5.2.4 Clostridioides difficile
  • 5.2.5 Listeria monocytogenes
• 5.3 By Disease Indication
  • 5.3.1 Pneumonia
  • 5.3.2 Sepsis / BSI
  • 5.3.3 Skin & Soft-Tissue Infections
  • 5.3.4 Pharyngitis (Strep throat)
  • 5.3.5 Endocarditis
  • 5.3.6 Meningitis
• 5.4 By End User
  • 5.4.1 Hospitals
  • 5.4.2 Reference Laboratories
  • 5.4.3 Ambulatory Surgery Centers
  • 5.4.4 Retail & Online Pharmacies
• 5.5 By Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 South America
    • 5.5.2.1 Brazil
    • 5.5.2.2 Argentina
    • 5.5.2.3 Rest of South America
  • 5.5.3 Europe
    • 5.5.3.1 Germany
    • 5.5.3.2 United Kingdom
    • 5.5.3.3 France
    • 5.5.3.4 Italy
    • 5.5.3.5 Spain
    • 5.5.3.6 Rest of Europe
  • 5.5.4 Asia-Pacific
    • 5.5.4.1 China
    • 5.5.4.2 Japan
    • 5.5.4.3 India
    • 5.5.4.4 South Korea
    • 5.5.4.5 Australia
    • 5.5.4.6 Rest of Asia-Pacific
  • 5.5.5 Middle East & Africa
    • 5.5.5.1 GCC
    • 5.5.5.2 South Africa
    • 5.5.5.3 Rest of Middle East & Africa
  • 5.5.6 South America
    • 5.5.6.1 Brazil
    • 5.5.6.2 Argentina
    • 5.5.6.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global Overview, Market Level Overview, Core Segments, Financials as available, Strategic Info, Market Rank/Share, Products & Services, Recent Developments)
  • 6.3.1 Abbott Laboratories
  • 6.3.2 AstraZeneca plc
  • 6.3.3 Basilea Pharmaceutica Ltd.
  • 6.3.4 Becton Dickinson & Co.
  • 6.3.5 bioMerieux SA
  • 6.3.6 Cepheid (Danaher)
  • 6.3.7 Cumberland Pharmaceuticals
  • 6.3.8 Dr Reddy's Laboratories Ltd.
  • 6.3.9 GlaxoSmithKline plc
  • 6.3.10 Hikma Pharmaceuticals plc
  • 6.3.11 Johnson & Johnson (Janssen)
  • 6.3.12 Lupin Ltd.
  • 6.3.13 Melinta Therapeutics
  • 6.3.14 Merck & Co., Inc.
  • 6.3.15 Novartis AG
  • 6.3.16 Paratek Pharmaceuticals
  • 6.3.17 Pfizer Inc.
  • 6.3.18 Hoffmann-La Roche Ltd
  • 6.3.19 Sanofi SA
  • 6.3.20 Shionogi & Co., Ltd.
  • 6.3.21 Sun Pharma Industries Ltd.
  • 6.3.22 Thermo Fisher Scientific Inc.

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-Need Assessment